

Supplemental Table. Characteristics of patient in PIV-3 antibody cohort and other patients who received allogeneic transplants during the study period, 1992-2009

	Patients with Ab titers (n=172)	Patients without Ab titers (n=178)	p value
Sex			0.52
Male	111 (65)	109 (61)	
Female	61 (35)	69 (39)	
Age at HCT^a	41 (1-72)	37 (0.4-73)	0.01
Disease risk at HCT			0.14
Standard	101 (59)	118 (66)	
High	71 (41)	60 (34)	
Transplant year			0.42
1992-2000	99 (58)	110 (62)	
2001-2009	73 (42)	68 (38)	
Stem cell source			0.20
Bone marrow	97 (56)	107 (60)	
Peripheral blood stem cell	72 (42)	63 (35)	
Cord blood	3 (2)	8 (4)	
Donor type			0.001
Related	104 (60)	77 (43)	
Unrelated	68 (40)	101 (57)	
Conditioning regimen			0.61
MA including high-dose TBI (≥ 12 Gy)	75 (44)	87 (49)	
MA \pm low-dose TBI (≤ 2 Gy)	63 (37)	60 (34)	
Reduced intensity ^b	34 (20)	31 (17)	
GVHD prophylaxis^c			0.07
MTX + CNI	109 (63)	133 (75)	
MMF + CNI	41 (24)	31 (17)	
Other	22 (13)	14 (8)	
Days between HCT and infection			<0.001
≤ 30	33 (19)	35 (20)	
31-365	135 (78)	104 (58)	
> 365	4 (2)	39 (22)	
Lymphocyte count at diagnosis^d			0.25
> 500 $\times 10^6$ /L	61 (35)	64 (36)	
100-500 $\times 10^6$ /L	82 (48)	86 (48)	
< 100 $\times 10^6$ /L	26 (15)	19 (11)	
Co-pathogen^e			0.05
None	148 (86)	146 (82)	
Any pathogen	24 (14)	26 (15)	

All values are indicated as the number (percentage).

^a Values are indicated as the median (range). ^b Reduced intensity regimens consisted mainly of fludarabine with 2 Gy TBI. ^c MTX + CNI group includes MTX alone (n=4), MMF + CNI includes MMF alone (n=1), other includes CNI alone and CNI+steroid. ^d Data missing for 3 patients in antibody cohort and 9 patients in comparator cohort. ^e Data missing for 6 HCT: hematopoietic cell transplantation, MA: myeloablative, TBI: total body irradiation, CNI: calcineurin inhibitor, MTX: methotrexate, MMF: mycophenolate mofetil